Hipogonadismo en hombres

Referencias

Artículos principales

Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA Guideline. J Urol. 2018 Mar 28. pii: S0022-5347(18)42817-0. [Epub ahead of print]Texto completo  Resumen

Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007 Nov;92(11):4241-7.Texto completo  Resumen

Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004 Dec;89(12):5920-6.Texto completo  Resumen

Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 Mar 17. [Epub ahead of print]Texto completo  Resumen

Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011 Jul;34(7):1669-75.Texto completo  Resumen

Snyder PJ, Bhasin S, Cunningham GR, et al; Testosterone Trials Investigators. Effects of testosterone treatment in older men. N Engl J Med. 2016 Feb 18;374(7):611-24.Texto completo  Resumen

Artículos de referencia

1. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA Guideline. J Urol. 2018 Mar 28. pii: S0022-5347(18)42817-0. [Epub ahead of print]Texto completo  Resumen

2. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015 Mar;18(1):5-15.Texto completo  Resumen

3. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008 Nov;159(5):507-14.Texto completo  Resumen

4. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007 Nov;92(11):4241-7.Texto completo  Resumen

5. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004 Dec;89(12):5920-6.Texto completo  Resumen

6. Tajar A, Forti G, O'Neill TW, et al; EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. J Clin Endocrinol Metab. 2010 Apr;95(4):1810-8. Resumen

7. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 Mar 17. [Epub ahead of print]Texto completo  Resumen

8. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab. 2003 Feb;88(2):622-6.Texto completo  Resumen

9. Groth KA, Skakkebæk A, Høst C, et al. Clinical review: Klinefelter syndrome - a clinical update. J Clin Endocrinol Metab. 2013 Jan;98(1):20-30.Texto completo  Resumen

10. Friedman NM, Plymate SR. Leydig cell dysfunction and gynaecomastia in adult males treated with alkylating agents. Clin Endocrinol (Oxf). 1980 Jun;12(6):553-6. Resumen

11. Whitcomb RW, Crowley WF Jr. Clinical Review 4: Diagnosis and treatment of isolated gonadotropin-releasing hormone deficiency in men. J Clin Endocrinol Metab. 1990 Jan;70(1):3-7. Resumen

12. Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011 Jul;34(7):1669-75.Texto completo  Resumen

13. Grant NN, Anawalt BD. Male hypogonadism in the primary care clinic. Prim Care. 2003 Dec;30(4):743-63. Resumen

14. Buvat J, Maggi M, Guay A, et al. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013 Jan;10(1):245-84. Resumen

15. Rochira V, Balestrieri A, Madeo B, et al. Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men. Mol Cell Endocrinol. 2002 Jul 31;193(1-2):19-28. Resumen

16. Layman LC. Hypogonadotropic hypogonadism. Endocrinol Metab Clin North Am. 2007 Jun;36(2):283-96. Resumen

17. Braunstein GD. Gynecomastia. N Engl J Med. 2007 Sep 20;357(12):1229-37. Resumen

18. Ferlin A, Arredi B, Speltra E, et al. Molecular and clinical characterization of Y chromosome microdeletions in infertile men: a 10-year experience in Italy. J Clin Endocrinol Metab. 2007 Mar;92(3):762-70.Texto completo  Resumen

19. Ring J, Welliver C, Parenteau M, et al. The utility of sex hormone-binding globulin in hypogonadism and infertile males. J Urol. 2017 May;197(5):1326-31. Resumen

20. Paduch DA, Brannigan RE, Fuchs EF, et al. The laboratory diagnosis of testosterone deficiency. Urology. 2014 May;83(5):980-8. Resumen

21. Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010 May-Jun;16(3):231-45.Texto completo  Resumen

22. European Association of Urology. Non-oncology guidelines: male sexual dysfunction. 2018 [internet publication].Texto completo

23. Shabsigh R, Kaufman JM, Steidle C, et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2008 May;179(suppl 5):S97-102. Resumen

24. Chiang HS, Hwang TI, Hsui YS, et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res. 2007 Jul-Aug;19(4):411-7.Texto completo  Resumen

25. Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment - a systematic review. Eur Urol. 2014 Jan;65(1):99-112.Texto completo  Resumen

26. Edelstein D, Dobs A, Basaria S. Emerging drugs for hypogonadism. Expert Opin Emerg Drugs. 2006 Nov;11(4):685-707. Resumen

27. Edelstein D, Sivanandy M, Shahani S, et al. The latest options and future agents for treating male hypogonadism. Expert Opin Pharmacother. 2007 Dec;8(17):2991-3008. Resumen

28. Spratt DI, Finkelstein JS, O'Dea LS, et al. Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism. A model for studies of the hormone's physiologic effects. Ann Intern Med. 1986 Dec;105(6):848-55. Resumen

29. Parker A, Bruha M, Akinola O, et al. A summary of the controversy surrounding off-label medications in men's health. Transl Androl Urol. 2016 Apr;5(2):201-6.Texto completo  Resumen

30. Elliott J, Kelly SE, Millar AC, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017 Nov 16;7(11):e015284.Texto completo  Resumen

31. Kaufman JM, Miller MG, Garwin JL, et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med. 2011 Jul;8(7):2079-89. Resumen

32. Jordan WP Jr. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am J Contact Dermat. 1997 Jun;8(2):108-13. Resumen

33. Delanoe D, Fougeyrollas B, Meyer L, et al. Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet. 1984 Feb 4;1(8371):276. Resumen

34. Moore N, Paux G, Noblet C, et al. Spouse-related drug side-effects. Lancet. 1988 Feb 27;1(8583):468. Resumen

35. Yu YM, Punyasavatsu N, Elder D, et al. Sexual development in a two-year-old boy induced by topical exposure to testosterone. Pediatrics. 1999 Aug;104(2):e23.Texto completo  Resumen

36. American Society of Andrology. Testosterone replacement therapy for male aging: ASA position statement. J Androl. 2006 Mar-Apr;27(2):133-4.Texto completo  Resumen

37. Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006 Jan;27(1):57-64.Texto completo  Resumen

38. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009 Sep 1;54(10):919-27.Texto completo  Resumen

39. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010 Jul 8;363(2):109-22.Texto completo  Resumen

40. Carson CC 3rd, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med. 2012 Jan;9(1):54-67. Resumen

41. English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000 Oct 17;102(16):1906-11.Texto completo  Resumen

42. Jones TH, Arver S, Behre HM, et al; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011 Apr;34(4):828-37.Texto completo  Resumen

43. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010 Feb;95(2):639-50.Texto completo  Resumen

44. Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015 Oct 21;36(40):2706-15.Texto completo  Resumen

45. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013 Nov 6;310(17):1829-36. Resumen

46. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004 Jul;89(7):3313-8.Texto completo  Resumen

47. Liu PY, Yee B, Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab. 2003 Aug;88(8):3605-13.Texto completo  Resumen

48. Haider A, Haider KS, Saad F. Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy. Endocrinol Diabetes Metab Case Rep. 2017 Sep 4;2017. pii: 17-0084.Texto completo  Resumen

49. Hackett G, Cole N, Saghir A, et al. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology. 2017 Sep;5(5):905-13. Resumen

50. Pastuszak AW, Kohn TP, Estis J, et al. Low plasma testosterone is associated with elevated cardiovascular disease biomarkers. J Sex Med. 2017 Sep;14(9):1095-103. Resumen

51. Kohn TP, Mata DA, Ramasamy R, et al. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016 Jun;69(6):1083-90. Resumen

52. Snyder PJ, Bhasin S, Cunningham GR, et al; Testosterone Trials Investigators. Effects of testosterone treatment in older men. N Engl J Med. 2016 Feb 18;374(7):611-24.Texto completo  Resumen

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad